Latest

• Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall.

  When the understanding of relevant science no longer supports prior interpretation of a test result, is there a duty to recontact previously tested patients to inform them of the implications of these changes? »

• Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.

  PMPRB regulatory changes will likely cause a substantial decline in the number of industry-funded clinical trials in Canada. »

• Medical resources and spending across provincial healthcare systems in Canada.

  Analysis links the availability of new drugs to lower overall health spending. »

• HTA and public coverage of new mental health drugs in Quebec and Canada.

  INESSS v CDR and RAMQ v ROC »

• Medical Resources in Canada and OECD countries. 2019 Edition.

  Canada’s health system supplies patients with fewer medical resources than the health systems of most OECD countries. »

• Evidence that innovative medicines improve health and economic outcomes: focused literature review.

  There is abundant empirical evidence that pharmaceutical innovation improves population-level health outcomes and societal-level net economic benefits. »

• Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options.

  Study weighs the options being considered by the federal Advisory Council on the Implementation of National Pharmacare. »

• Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018.

  The pCPA should demonstrate to Canadians that its negotiations to contain the costs of new drugs are not limiting patients’ access to innovative drugs. »

• Facts about the cost of patented drugs in Canada: 2018 Edition.

  Policymakers are not fully informed about pharmaceutical costs - particularly regarding patented medicines. »